* Signs deal with five municipalities within Stockholm area: Nacka, Lidingö, Värmdö, Järfälla and Vaxholm
* Topline result of phase III study of CicloMulsion in acute myocardial infarction expected this quarter
* Says bilastine successfully completed two clinical pivotal studies of phase III in Japan
* SciBase, a Swedish medtech company that develops and markets a new method for early detection of malignant melanoma, has received approval from the United States Patent and trademark Office (USPTO) regarding its patent application for its electrodes with micro-needles
* Says has reached agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the Phase 3 study of tozadenant in Parkinson's disease(PD)
No related earnings announcements are currently scheduled within the next 7 days.